Massive-scale genetic risk profiling to guide personalized diabetes care
Official title: Massive-scale genomic risk assessment to inform precision medicine across the spectrum of monogenic and common forms of diabetes
Funded at Broad Institute, INC. · NIH-11596831 · Data updated 2026-11-12
A large NIH-funded project will study how many diabetes-related genetic variants influence risk across diverse populations to help tailor prevention and treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 19, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $32,400 |
| NIH project number | 3R01DK140545-02S2 |
| Project ID | NIH-11596831 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with suspected or confirmed diabetes, and those with a family history or genetic ancestry considerations that suggest monogenic or atypical forms.
✕Less likely to help
People without access to genomic testing or those not related to diabetes care may not directly benefit.
What this research studies
This project looks at how both common and rare genetic variants affect different forms of diabetes, including type 1, type 2, and monogenic diabetes, across people of diverse ancestries. By building a unified framework for interpreting these variants, the study aims to improve diagnostic accuracy and reporting for clinicians and patients. Researchers will analyze large genomic datasets and develop guidelines to translate genetic findings into personalized care strategies for diabetes patients and at-risk individuals.
Why it matters
Potential benefit: If successful, patients could receive more precise diagnoses and personalized treatment plans based on their genetic risk.
How similar studies have gone: Previous genetic studies have linked variants to diabetes risk, but this project seeks a unified, cross-ancestry framework to improve clarity and clinical utility.
Where this research is happening
-
Broad Institute, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Mercader, Josep Maria — Broad Institute, INC.
- Study coordinator: Mercader, Josep Maria
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Retinal signals in early diabetes and how they affect vision
This grant looks at how diabetes changes the signals in the retina that control vision, with a focus on inner retinal cells and how these changes may lead to vision problems.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Bringing WHO HEARTS-D diabetes care into Bangladesh cities
A program to help urban clinics in Bangladesh adopt WHO HEARTS-D guidelines to improve detection, treatment, and control of type 2 diabetes.
-
AI-powered fundus imaging to screen for type 2 diabetes
A mobile AI tool uses eye images to help screen adults for type 2 diabetes in clinics or communities.
-
AI-powered eye imaging to screen for type 2 diabetes with a mobile phone
A plan to use AI on smartphone retinal images to help spot type 2 diabetes early, especially in people who may not have easy access to care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.